Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
ACADEMIA
Osteoporosis Experts Express “Shock” at Discontinuation of Development of Odanacatib
Experts of osteoporosis treatments lamented the discontinuation of development of odanacatib, which was expected to be safer and more effective than existing drugs, at the annual meeting of the Japan Osteoporosis Society (JOS). Odanacatib, a cathepsin K inhibitor, was being…
To read the full story
Related Article
- Merck Ditches Osteoporosis Med Odanacatib from Global Pipelines
September 6, 2016
ACADEMIA
- Urine-Derived Stem Cells Eyed as New Drug Discovery Tool
June 10, 2026
- Japan Cancer Center Lowers Recommended BMI Ceiling for Men to 25
June 5, 2026
- Tavneos Data Integrity Issue Could Spill Over to Japan, Investigator Warns
June 2, 2026
- Arava Safety Backup at Risk as Questran Supply Falters on Nitrosamine Issue
May 11, 2026
- NCC Launches First Japan Trial for CP Inhibitor-Related Liver Dysfunction
April 27, 2026
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Recent trends are creating a fascinating push-and-pull effect in the talent market. We’re seeing more positions opening up, but also a greater number of candidates available, particularly in the fields of rare diseases and oncology. This “more positions, more candidates”…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…